CN100522166C - 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 - Google Patents

用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 Download PDF

Info

Publication number
CN100522166C
CN100522166C CNB038137798A CN03813779A CN100522166C CN 100522166 C CN100522166 C CN 100522166C CN B038137798 A CNB038137798 A CN B038137798A CN 03813779 A CN03813779 A CN 03813779A CN 100522166 C CN100522166 C CN 100522166C
Authority
CN
China
Prior art keywords
alkyl
aryl
compound
alkoxy
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038137798A
Other languages
English (en)
Chinese (zh)
Other versions
CN1658874A (zh
Inventor
Q·曾
R·G·阿斯拉尼安
M·Y·伯林
C·W·博伊斯
J·曹
J·A·科兹罗夫斯基
P·曼加拉茨纳
K·D·麦科尔米克
M·W·穆塔希
S·B·罗森布卢姆
N·-Y·施
D·M·索洛蒙
W·C·托姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1658874A publication Critical patent/CN1658874A/zh
Application granted granted Critical
Publication of CN100522166C publication Critical patent/CN100522166C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038137798A 2002-04-18 2003-04-16 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物 Expired - Fee Related CN100522166C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37373102P 2002-04-18 2002-04-18
US60/373,731 2002-04-18

Publications (2)

Publication Number Publication Date
CN1658874A CN1658874A (zh) 2005-08-24
CN100522166C true CN100522166C (zh) 2009-08-05

Family

ID=29251069

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038137798A Expired - Fee Related CN100522166C (zh) 2002-04-18 2003-04-16 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物

Country Status (26)

Country Link
EP (1) EP1499316B1 (enExample)
JP (1) JP4384918B2 (enExample)
KR (1) KR100827470B1 (enExample)
CN (1) CN100522166C (enExample)
AR (1) AR040405A1 (enExample)
AT (1) ATE389406T1 (enExample)
AU (1) AU2003223627B2 (enExample)
BR (1) BR0309348A (enExample)
CA (1) CA2481940A1 (enExample)
CY (1) CY1110363T1 (enExample)
DE (1) DE60319813T2 (enExample)
DK (1) DK1499316T3 (enExample)
EC (1) ECSP045367A (enExample)
ES (1) ES2301791T3 (enExample)
IL (1) IL164584A (enExample)
MX (1) MXPA04010173A (enExample)
NO (1) NO20045002L (enExample)
NZ (1) NZ535763A (enExample)
PE (1) PE20040684A1 (enExample)
PL (1) PL373889A1 (enExample)
PT (1) PT1499316E (enExample)
RU (1) RU2323935C2 (enExample)
SI (1) SI1499316T1 (enExample)
TW (1) TW200306183A (enExample)
WO (1) WO2003088967A1 (enExample)
ZA (1) ZA200407984B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050100615A (ko) 2003-01-14 2005-10-19 싸이토키네틱스, 인코포레이티드 화합물, 조성물 및 방법
AU2004238447C1 (en) 2003-04-23 2009-06-11 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
CA2570999C (en) 2004-06-17 2014-01-07 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006038738A1 (ja) * 2004-10-08 2006-04-13 Takeda Pharmaceutical Company Limited 受容体機能調節剤
CA2595157A1 (en) 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
EP1902046B1 (en) 2005-06-20 2009-12-02 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
US7408066B2 (en) 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
CA2623025A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
JP2009521448A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
KR20080085031A (ko) * 2006-01-13 2008-09-22 에프. 호프만-라 로슈 아게 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 ｈ3수용체 조절제로서의 이의 용도
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
CA2691782A1 (en) * 2007-09-11 2009-03-19 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
WO2011082270A2 (en) 2009-12-30 2011-07-07 Arqule. Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
WO2012177844A2 (en) 2011-06-24 2012-12-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
KR101127756B1 (ko) 2011-09-02 2012-03-23 한국과학기술원 Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP6046646B2 (ja) 2014-01-10 2016-12-21 信越化学工業株式会社 オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法
US10595550B2 (en) * 2014-01-22 2020-03-24 Vision Pharma, Llc Therapeutic composition including carbonated solution
US10118900B2 (en) 2015-08-25 2018-11-06 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as CB-1 inverse agonists
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580541A1 (en) * 1992-07-20 1994-01-26 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents
CN1211246A (zh) * 1996-02-21 1999-03-17 赫彻斯特马里恩鲁斯公司 用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－ (芳基)丁基)苯甲酰胺
CN1323302A (zh) * 1998-10-16 2001-11-21 先灵公司 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
WO2002032893A2 (en) * 2000-10-17 2002-04-25 Schering Corporation Piperidine compounds as anti-allergic

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD290192A5 (de) * 1986-11-13 1991-05-23 Eisai Co. Ltd,Jp Pyridinderivat mit antiulzeroeser wirkung
DE69415391T2 (de) * 1993-05-26 1999-08-26 Sumitomo Pharmaceuticals Co. Chinazolinonderivate
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
WO1998050368A1 (en) * 1997-05-01 1998-11-12 Nissan Chemical Industries, Ltd. Benzimidazole derivative
HK1052179A1 (zh) * 2000-09-20 2003-09-05 Schering Corporation 作为双重组胺h1和h3激动剂或拮抗剂的取代咪唑
NZ535764A (en) * 2002-04-18 2007-10-26 Schering Corp 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580541A1 (en) * 1992-07-20 1994-01-26 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) New piperidine derivatives of benzimidazole as antihistanminic and antiallergic agents
CN1211246A (zh) * 1996-02-21 1999-03-17 赫彻斯特马里恩鲁斯公司 用于治疗过敏性疾病的新的取代的n－甲基－n－(4－(4－(1h－苯并咪唑－2－基氨基)哌啶－1－基)－2－ (芳基)丁基)苯甲酰胺
CN1323302A (zh) * 1998-10-16 2001-11-21 先灵公司 作为组胺－h3激动剂或拮抗剂的n－(咪唑基烷基)取代的环胺
WO2002032893A2 (en) * 2000-10-17 2002-04-25 Schering Corporation Piperidine compounds as anti-allergic

Also Published As

Publication number Publication date
RU2004133764A (ru) 2005-07-20
TW200306183A (en) 2003-11-16
PT1499316E (pt) 2008-06-30
CA2481940A1 (en) 2003-10-30
WO2003088967A1 (en) 2003-10-30
PE20040684A1 (es) 2004-10-05
DK1499316T3 (da) 2008-07-21
HK1067981A1 (en) 2005-04-22
MXPA04010173A (es) 2005-02-03
CN1658874A (zh) 2005-08-24
EP1499316A1 (en) 2005-01-26
EP1499316B1 (en) 2008-03-19
JP2005529116A (ja) 2005-09-29
SI1499316T1 (sl) 2008-08-31
IL164584A (en) 2010-12-30
ES2301791T3 (es) 2008-07-01
DE60319813D1 (de) 2008-04-30
NO20045002L (no) 2005-01-18
KR100827470B1 (ko) 2008-05-06
ZA200407984B (en) 2005-10-18
JP4384918B2 (ja) 2009-12-16
AU2003223627B2 (en) 2006-10-12
KR20040099445A (ko) 2004-11-26
NZ535763A (en) 2007-06-29
AR040405A1 (es) 2005-04-06
RU2323935C2 (ru) 2008-05-10
CY1110363T1 (el) 2012-05-23
PL373889A1 (en) 2005-09-19
ECSP045367A (es) 2004-11-26
BR0309348A (pt) 2005-03-01
ATE389406T1 (de) 2008-04-15
AU2003223627C1 (en) 2003-11-03
IL164584A0 (en) 2005-12-18
DE60319813T2 (de) 2009-04-23
AU2003223627A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
CN100522166C (zh) 用作组胺h3拮抗剂的(1-4-哌啶基)苯并咪唑衍生物
CN100497334C (zh) 用作组胺h3拮抗剂的吲哚衍生物
CN100360130C (zh) 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
US7105505B2 (en) Benzimidazole derivatives useful as histamine H3 antagonists
JP4025200B2 (ja) ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用
CN109415359B (zh) 杂环gpr119激动剂化合物
JP2000514821A (ja) ピラゾロピリジン化合物およびその医薬用途
HK1067981B (en) (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
HK1101691A (en) Indole derivatives useful as histamine h3 antagonists
JPH1180157A (ja) ピラゾロピリジンアデノシン拮抗剤
HK1072259B (en) Indole derivatives useful as histamine h3 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20110416